U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Renal cortical microcysts

MedGen UID:
356391
Concept ID:
C1865877
Finding
Synonyms: Cortical microcysts; Multiple small renal cortical cysts
 
HPO: HP:0004734

Definition

Cysts of microscopic size confined to the cortex of the kidney. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRenal cortical microcysts

Conditions with this feature

Infantile nephronophthisis
MedGen UID:
355574
Concept ID:
C1865872
Disease or Syndrome
The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Løken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).
Nephronophthisis 9
MedGen UID:
462538
Concept ID:
C3151188
Disease or Syndrome
The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Løken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).
Peroxisome biogenesis disorder 5A (Zellweger)
MedGen UID:
766854
Concept ID:
C3553940
Disease or Syndrome
The peroxisomal biogenesis disorder (PBD) Zellweger syndrome (ZS) is an autosomal recessive multiple congenital anomaly syndrome. Affected children present in the newborn period with profound hypotonia, seizures, and inability to feed. Characteristic craniofacial anomalies, eye abnormalities, neuronal migration defects, hepatomegaly, and chondrodysplasia punctata are present. Children with this condition do not show any significant development and usually die in the first year of life (summary by Steinberg et al., 2006). For a complete phenotypic description and a discussion of genetic heterogeneity of Zellweger syndrome, see 214100. Individuals with PBDs of complementation group 5 (CG5, equivalent to CG10 and CGF) have mutations in the PEX2 gene. For information on the history of PBD complementation groups, see 214100.
Trichohepatoenteric syndrome 1
MedGen UID:
1644087
Concept ID:
C4551982
Disease or Syndrome
Trichohepatoenteric syndrome (THES), generally considered to be a neonatal enteropathy, is characterized by intractable diarrhea (seen in almost all affected children), woolly hair (seen in all), intrauterine growth restriction, facial dysmorphism, and short stature. Additional findings include poorly characterized immunodeficiency, recurrent infections, skin abnormalities, and liver disease. Mild intellectual disability (ID) is seen in about 50% of affected individuals. Less common findings include congenital heart defects and platelet anomalies. To date 52 affected individuals have been reported.
Peroxisome biogenesis disorder 1A (Zellweger)
MedGen UID:
1648474
Concept ID:
C4721541
Disease or Syndrome
Zellweger spectrum disorder (ZSD) is a phenotypic continuum ranging from severe to mild. While individual phenotypes (e.g., Zellweger syndrome [ZS], neonatal adrenoleukodystrophy [NALD], and infantile Refsum disease [IRD]) were described in the past before the biochemical and molecular bases of this spectrum were fully determined, the term "ZSD" is now used to refer to all individuals with a defect in one of the ZSD-PEX genes regardless of phenotype. Individuals with ZSD usually come to clinical attention in the newborn period or later in childhood. Affected newborns are hypotonic and feed poorly. They have distinctive facies, congenital malformations (neuronal migration defects associated with neonatal-onset seizures, renal cysts, and bony stippling [chondrodysplasia punctata] of the patella[e] and the long bones), and liver disease that can be severe. Infants with severe ZSD are significantly impaired and typically die during the first year of life, usually having made no developmental progress. Individuals with intermediate/milder ZSD do not have congenital malformations, but rather progressive peroxisome dysfunction variably manifest as sensory loss (secondary to retinal dystrophy and sensorineural hearing loss), neurologic involvement (ataxia, polyneuropathy, and leukodystrophy), liver dysfunction, adrenal insufficiency, and renal oxalate stones. While hypotonia and developmental delays are typical, intellect can be normal. Some have osteopenia; almost all have ameleogenesis imperfecta in the secondary teeth.

Professional guidelines

PubMed

Aurell M, Svalander C, Wallin L, Alling C
Kidney Int 1981 Nov;20(5):663-70. doi: 10.1038/ki.1981.191. PMID: 7343714

Recent clinical studies

Etiology

Iorio P, Heidet L, Rutten C, Garcelon N, Audrézet MP, Morinière V, Boddaert N, Salomon R, Berteloot L
Pediatr Nephrol 2020 Jun;35(6):1033-1040. Epub 2020 Feb 10 doi: 10.1007/s00467-020-04480-z. PMID: 32040628
Berte N, Vrillon I, Larmure O, Gomola V, Ayav C, Mazeaud C, Lemelle JL
Prog Urol 2018 Oct;28(12):596-602. Epub 2018 Jul 3 doi: 10.1016/j.purol.2018.06.005. PMID: 29980359
Medapalli RK, He JC, Klotman PE
Curr Opin Nephrol Hypertens 2011 May;20(3):306-11. doi: 10.1097/MNH.0b013e328345359a. PMID: 21358326Free PMC Article
Depreter M, Espeel M, Roels F
Microsc Res Tech 2003 Jun 1;61(2):203-23. doi: 10.1002/jemt.10330. PMID: 12740827
George CR, Hickman RO, Stricker GE
Clin Nephrol 1976 Jan;5(1):20-4. PMID: 765027

Diagnosis

Iorio P, Heidet L, Rutten C, Garcelon N, Audrézet MP, Morinière V, Boddaert N, Salomon R, Berteloot L
Pediatr Nephrol 2020 Jun;35(6):1033-1040. Epub 2020 Feb 10 doi: 10.1007/s00467-020-04480-z. PMID: 32040628
Roque A, Herédia V, Ramalho M, de Campos R, Ferreira A, Azevedo R, Semelka R
Abdom Imaging 2012 Feb;37(1):140-6. doi: 10.1007/s00261-011-9745-6. PMID: 21717136
Tuazon J, Casalino D, Syed E, Batlle D
ScientificWorldJournal 2008 Aug 31;8:828-9. doi: 10.1100/tsw.2008.112. PMID: 18758659Free PMC Article
Depreter M, Espeel M, Roels F
Microsc Res Tech 2003 Jun 1;61(2):203-23. doi: 10.1002/jemt.10330. PMID: 12740827
Gagnadoux MF, Bacri JL, Broyer M, Habib R
Pediatr Nephrol 1989 Jan;3(1):50-5. doi: 10.1007/BF00859626. PMID: 2702088

Therapy

Katuri A, Bryant JL, Patel D, Patel V, Andhavarapu S, Asemu G, Davis H, Makar TK
Exp Mol Pathol 2019 Feb;106:139-148. Epub 2018 Dec 31 doi: 10.1016/j.yexmp.2018.12.009. PMID: 30605635
Yadav A, Kumar D, Salhan D, Rattanavich R, Maheshwari S, Adabala M, Ding G, Singhal PC
Exp Mol Pathol 2012 Aug;93(1):173-81. Epub 2012 May 2 doi: 10.1016/j.yexmp.2012.04.021. PMID: 22579465Free PMC Article
Roque A, Herédia V, Ramalho M, de Campos R, Ferreira A, Azevedo R, Semelka R
Abdom Imaging 2012 Feb;37(1):140-6. doi: 10.1007/s00261-011-9745-6. PMID: 21717136
Farres MT, Ronco P, Saadoun D, Remy P, Vincent F, Khalil A, Le Blanche AF
Radiology 2003 Nov;229(2):570-4. doi: 10.1148/radiol.2292020758. PMID: 14595154
George CR, Hickman RO, Stricker GE
Clin Nephrol 1976 Jan;5(1):20-4. PMID: 765027

Prognosis

Berte N, Vrillon I, Larmure O, Gomola V, Ayav C, Mazeaud C, Lemelle JL
Prog Urol 2018 Oct;28(12):596-602. Epub 2018 Jul 3 doi: 10.1016/j.purol.2018.06.005. PMID: 29980359
Mohan S, Herlitz LC, Tan J, Cheng JT, Anderson HL, Stokes MB, Markowitz GS, D'Agati VD, Radhakrishnan J
Clin Nephrol 2013 Apr;79(4):285-91. doi: 10.5414/CN107774. PMID: 23320974
Salvatore SP, Barisoni LM, Herzenberg AM, Chander PN, Nickeleit V, Seshan SV
Clin J Am Soc Nephrol 2012 Jun;7(6):914-25. Epub 2012 Mar 29 doi: 10.2215/CJN.11751111. PMID: 22461531
Depreter M, Espeel M, Roels F
Microsc Res Tech 2003 Jun 1;61(2):203-23. doi: 10.1002/jemt.10330. PMID: 12740827
Laurinavicius A, Rennke HG
Semin Diagn Pathol 2002 Aug;19(3):106-15. PMID: 12180632

Clinical prediction guides

Berte N, Vrillon I, Larmure O, Gomola V, Ayav C, Mazeaud C, Lemelle JL
Prog Urol 2018 Oct;28(12):596-602. Epub 2018 Jul 3 doi: 10.1016/j.purol.2018.06.005. PMID: 29980359
Roque A, Herédia V, Ramalho M, de Campos R, Ferreira A, Azevedo R, Semelka R
Abdom Imaging 2012 Feb;37(1):140-6. doi: 10.1007/s00261-011-9745-6. PMID: 21717136
Salomon R, Saunier S, Niaudet P
Pediatr Nephrol 2009 Dec;24(12):2333-44. Epub 2008 Jul 8 doi: 10.1007/s00467-008-0840-z. PMID: 18607645Free PMC Article
D'Agati V, Suh JI, Carbone L, Cheng JT, Appel G
Kidney Int 1989 Jun;35(6):1358-70. doi: 10.1038/ki.1989.135. PMID: 2770114
Gagnadoux MF, Bacri JL, Broyer M, Habib R
Pediatr Nephrol 1989 Jan;3(1):50-5. doi: 10.1007/BF00859626. PMID: 2702088

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...